|
CN111363039A
|
|
anti-PD-L1 antibody suitable for immunohistochemical detection
|
|
CN111346225A
|
|
Pharmaceutical formulations containing proteins
|
|
CN110878319A
|
|
Preparation method of TNF (tumor necrosis factor) related activation induced cytokine
|
|
CN110878122A
|
|
Recombinant anti-PD-L1 monoclonal antibody
|
|
EP3356416A1
|
|
Pd-1 antibodies and uses thereof
|
|
CN106606784A
|
|
Probody conjugating drug for targeting tumor cells expressing EGFR, and applications thereof
|
|
CN106381287A
|
|
Method for culturing animal cells for over expression of lactic dehydrogenase C
|
|
CN106188251A
|
|
A kind of immunoglobulin-binding proteins mutant and application thereof
|
|
CN105821077A
|
|
Novel eukaryotic expression system, construction method and application thereof
|
|
CN105820248A
|
|
Method for preparing novel anti-EGFR monoclonal antibody and application thereof
|
|
CN105820246A
|
|
Method for preparing novel recombinant anti-TNF alpha chimeric monoclonal antibody and application thereof
|
|
CN104911166A
|
|
Novel recombinant medaka enteropeptidase light chain protein
|
|
CN105732811A
|
|
Novel anti-CD20 antibody nanometer array and its preparation method and use
|
|
CN104922067A
|
|
Drug-loading nano-liposome, and preparation method and application thereof
|
|
CN104910275A
|
|
Novel anti-epidermal growth factor receptor antibody, preparation method and application thereof
|
|
CN104592390A
|
|
Bispecific recombinant anti-HBsAg antibody, and preparation method and application thereof
|
|
CN104558194A
|
|
Anti-CD20-Flex bi-functional fusion protein as well as preparation method and application thereof
|
|
CN104418952A
|
|
Anti-ErbB2 bispecific antibody for treating breast cancer
|
